Serum Receptor Activator of Nuclear Factor-κ B Ligand, Osteoprotegrin, and Intact Parathyroid Hormone in Hemodialysis and Renal Transplant Patients

Therapeutic Apheresis and Dialysis

Volumn 16, Issue 6, 2012, Pages 600-604

  Rashtchizadeh, Nadereh ^a   Ghorbanihaghjo, Amir ^b   Argani, Hassan ^a   Mahmoudi Meimand, Saeed ^a   Safa, Javid ^a   Vatankhahan, Hamidreza ^a   Shahidi, Maryam ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hemodialysis; Kidney transplanted patients; Osteoprotegrin; Serum receptor activator of nuclear factor B ligand

Indexed keywords

CALCIUM; INTACT PARATHYROID HORMONE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGRIN; PARATHYROID HORMONE; PHOSPHORUS; PROTEGRIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CALCIUM BLOOD LEVEL; FEMALE; GRAFT RECIPIENT; HEMODIALYSIS PATIENT; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGE FACTORS; CALCINOSIS; CALCIUM; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHORUS; RANK LIGAND; RENAL DIALYSIS; RENAL INSUFFICIENCY; TIME FACTORS;

EID: 84870524145     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2012.01097.x     Document Type: Article

References (25)

1. Nitta K, Akiba T, Uchida K etal. Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification in hemodialysis patients. Hypertens Res 2004;27:47-52.
2. London GM, Marty C, Marchais SJ etal. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004;15:1943-51.
3. Rattanakul C, Lenbury Y, Krishnamara N etal. Modeling of bone formation and resorption mediated by parathyroid hormone: response to estrogen/PTH therapy. Biosystems 2003;70:55-72.
4. Hofbauer LC, Khosla S, Dunstan CR etal. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2-12.
5. Sato T, Tominaga Y, Iwasaki Y etal. Osteoprotegerin levels before and after renal transplantation. Am J Kidney Dis 2001;38:S175-S177.
6. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 2008;473:139-46.
7. Papadopouli AE, Klonaris CN, Theocharis SE. Role of OPG/RANKL/RANK axis on the vasculature. Histol Histopathol 2008;23:497-506.
8. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 2001;79:243-53.
9. Nikodimopoulou M, Liakos S. Secondary hyperparathyroidism and target organs in chronic kidney disease. Hippokratia 2011;15:33-8.
10. Huang JC, Sakata T, Pfelger LL etal. PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res 2004;19:235-44.
11. Kaden JJ, Bickelhaupt S, Grobholz R etal. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 2004;36:57-66.
12. Lieb W, Gona P, Larson MG etal. Biomarkers of the osteoprotegerin pathway:clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol 2010;30:1849-54.
13. Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009;204:321-29.
14. Mogelvang R, Pedersen SH, Flyvbjerg A etal. Comparison of osteoprotegerin to traditional atherosclerotic risk factors and high-sensitivity C-reactive protein for diagnosis of atherosclerosis. Am J Cardiol 2012;109:515-20.
15. Abedin M, Omland T, Ueland T etal. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 2007;99:513-18.
16. Alexopoulou O, Jamart J, Devogelaer JP etal. Bone density and markers of bone remodeling in type 1 male diabetic patients. Diabetes Metab 2006;32:453-8.
17. Doi S, Yorioka N, Masaki T etal. Increased serum osteoprotegerin level in older and diabetic hemodialysis patients. Ther Apher Dial 2004;8:335-9.
18. Gonnelli S, Montagnani A, Caffarelli C etal. Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis. J Endocrinol Invest 2005;28:534-9.
19. Urena P, Ferreira A, Morieux C etal. PTH/PTHrP receptor mRNA is down-regulated in epiphyseal cartilage growth plate of uraemic rats. Nephrol Dial Transplant 1996;11:2008-16.
20. Kazama JJ, Shigematsu T, Yano K etal. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002;39:525-32.
21. Doumouchtsis K, Perrea D, Doumouchtsis S etal. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease. Ther Apher Dial 2009;13:49-55.
22. Malyszko J, Malyszko JS, Wolczynski S, Mysliwiec M. Osteoprotegerin and its correlations with new markers of bone formation and bone resorption in kidney transplant recipients. Transplant Proc 2003;35:2227-9.
23. Hofbauer LC, Shui C, Riggs BL etal. Effects of immunosuppressants on receptor activator of NF-κB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 2001;280:334-9.
24. Watson P, Lazowski D, Han V etal. Parathyroid hormone restores bone mass and enhances osteoblast insulin-like growth factor I gene expression in ovariectomized rats. Bone 1995;16:357-65.
25. Lum L, Wong BR, Josien R etal. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 1999;274:13613-18.